2026 Interim report
Filed with HKEX · Stock code 6938 · · 93 pages · English
2 Definitions and Glossary of Technical Terms 8 Corporate Information 10 Financial Highlights 11 Management Discussion and Analysis 36 Corporate Governance and Other Information 69 Independent Review Report 70 Interim Condensed Consolidated Statement of Profit or Loss 71 Interim Condensed Consolidated Statement of Comprehensive Income 72 Interim Condensed Consolidated Statement of Financial Positi
Suzhou Ribo Life Science Co. Ltd. on 6ix
Earlier from Suzhou Ribo Life Science
- Next Day Disclosure Return
- Ribo Announces Strategic Collaboration with Insilico Medicine to Accelerate siRNA Drug Development Driven by AI
- Ribo and Boehringer Ingelheim further progress their siRNA program for metabolic dysfunction-associated steatohepatitis (MASH)
- Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH
- Ribo Life Science (06938.HK) Successfully Lists on the Main Board of the Hong Kong Stock Exchange
Later from Suzhou Ribo Life Science
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement - phase i clinical trial application submission of RBD3133 injection for overweight and obesity
Follow Suzhou Ribo Life Science into a list and get an email when it puts out news.
Follow Suzhou Ribo Life Science